Pharmacokinetic allometric scaling of antibodies: Application to the first-in-human dose estimation

Journal of Pharmaceutical Sciences

Volumn 98, Issue 10, 2009, Pages 3850-3861

  Mahmood, Iftekhar ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Antibodies; Clearance; Elimination half life; First in human dose; Interspecies pharmacokinetic scaling; Volume of distribution

Indexed keywords

AB 02; BEMEGRIDE; DIGOXIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LENERCEPT; MONOCLONAL ANTIBODY; RSHZ 19; SGN 40; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ALLOMETRY; ARTICLE; BODY WEIGHT; BRAIN WEIGHT; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; NONHUMAN;

EID: 69949109408     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21682     Document Type: Article

References (31)

1. Boxenbaum H, Dilea C. 1995. First-time-in-human dose selection: Allometric thoughts and perspectives. J Clin Pharmacol 35:957-966.
2. Mahmood I, Green MD, Fisher JE. 2003. Selection of the first-time dose in humans: Comparison of different approaches based on interspecies scaling of clearance. J Clin Pharmacol 43:692-697. (Pubitemid 36759146)
3. Mahmood I. 2005. First-in-human dose selection. In: Interspecies pharmacokinetic scaling: Principles and application of allometric scaling. Rockville, MD: Pine House Publishers. pp. 259-287.
4. Mahmood I, Balian JD. 1996. Interspecies scaling: Predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887-895.
5. Boxenbaum H, Fertig JB. 1984. Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species. Eur J Drug Metab Pharmacokin 9:177-183. (Pubitemid 14077557)
6. Lave TH, Dupin S, Schmitt C, Chou RC, Jaeck D, Coassolo PH. 1997. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: Application to 10 extensively metabolized drugs. J Pharm Sci 86:584-590. (Pubitemid 27203406)
7. Obach RS, Baxter JG, Liston TE, Silber BM, Jones C, Macintyre F, Rance DJ, Wastall P. 1997. The prediction of human pharmacokinetic parameters from pre-clinical and in vitro metabolism. J Pharmacol Exp Ther 283:46-58. (Pubitemid 27438945)
8. Mahmood I. 1998. Interspecies scaling of renally secreted drugs. Life Sci 63:2365-2371. (Pubitemid 28557275)
9. Mahmood I. 2005. Interspecies scaling of biliary excreted drugs: A comparison of several methods. J Pharm Sci 94:883-892. (Pubitemid 40577320)
10. Tang H, Mayersohn M. 2005. A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Dispos 33:1297-1303. (Pubitemid 41196972)
11. Mahmood I. 2006. Prediction of human drug clearance from animal data: Application of the rule of exponents and 'fu Corrected Intercept Method' (FCIM). J Pharm Sci 95:1810-1821. (Pubitemid 44229587)
12. Sinha VK, De Buck SS, Fenu LA, Smit JW, Nijsen M, Gilissen RA, Van Peer A, Lavrijsen K, Mackie CE. 2008. Predicting oral clearance in humans: How close can we get with allometry? Clin Pharmacokinet 47:35-45.
13. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. 1991. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 8:1351-1359.
14. Mahmood I, Worobec A. 2006. Therapeutic monoclonal antibodies. In: Mahmood I, editor. Clinical pharmacology of therapeutic proteins. Rockville, MD: Pine House Publishers. pp. 357-411.
15. Mahmood I. 2004. Interspecies scaling of protein drugs: Prediction of clearance from animals to humans. J Pharm Sci 93:177-185. (Pubitemid 38081825)
16. Sacher G. 1959. Relation of lifespan to brain weight and body weight in mammals. In: Wolstenholme GEW, O'Connor M, editors. CIBA Foundation colloquia on aging. London: Churchill. pp. 115-133.
17. U.S. Food and Drug Administration. 2003. Draft guidance for industry and reviewers: Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers. Fed Reg 68:2340-2341.
18. Boxenbaum H. 1982. Comparative pharmacokinetics of benzodiazepines in dog and man. J Pharmacokinet Biopharm 10:411-426. (Pubitemid 13217281)
19. Caldwell GW, Masucci JA, Yan Z, Hageman W. 2004. Allometric scaling of pharmacokinetic parameters in drug discovery: Can human CL, Vss and t1/2 be predicted from in-vivo rat data? Eur J Drug Metab Pharmacokinet 29:133-143.
20. Bazin-Redureau M, Pepin S, Hong G, Debray M, Scherrmann JM. 1998. Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2. Toxicol Appl Pharmacol 150:295-300. (Pubitemid 28302513)
21. Ho M, Silamut K, White NJ, Karbwang J, Looareesuwan S, Phillips RE, Warrell DA. 1990. Pharmacokinetics of three commercial antivenoms in patients envenomed by the Malayan pit viper, Calloselasma rhodostoma, in Thailand. Am J Trop Med Hyg 42:260-266. (Pubitemid 20109050)
22. Grene-Lerouge NAM, Bazin-Redurea MI, Debray M, Scherrmann JMG. 1996. Interspecies scaling of clearance and volume of distribution for digoxin specific fab. Toxicol Appl Pharmacol 138:84-89. (Pubitemid 26159598)
23. Ujhelyi MR, Robert S. 1995. Pharmacokinetic aspects of digioxin-specific fab therapy in the management of digitalis toxicity. Clin Pharmacokinet 28:483-493.
24. Davis CB, Hepburn TW, Urbanski JJ, Kwok DC, Hart TK, Herzyk DJ, Demuth SG, Leland M, Rhodes GR. 1995. Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19. Drug Metab Dispos 23:1028-1036.
25. Everitt DE, Davis CB, Thompson K, DiCicco R, Ilson B, Demuth SG, Herzyk DJ, Jorkasky DK. 1996. The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers. J Infect Dis 174:463-469. (Pubitemid 26299677)
26. Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, Modi NB. 1999. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288:371-378. (Pubitemid 29113511)
27. Gordon MS, Margolin K, Talpaz M, Sledge GW, Jr., Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D. 2001. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850. (Pubitemid 32119100)
28. Ducongé J, Fernández-Sánchez E, Alvarez D. 2004. Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: Is it really suitable? Biopharm Drug Dispos 25:177-186.
29. Richter WF, Gallati H, Schiller CD. 1999. Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans. Drug Metab Dispos 27:21-25. (Pubitemid 29060995)
30. Kelley SK, Gelzleichter T, Xie D, Lee WP, Darbonne WC, Qureshi F, Kissler K, Oflazoglu E, Grewal IS. 2006. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol 148:1116-1123. (Pubitemid 44223017)
31. Vugmeyster Y, Szklut P, Tchistiakova L, Abraham W, Kasaian M, Xu X. 2008. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms. Int Immunopharmacol 8:477-483.